GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Broncus Holding Corp (HKSE:02216) » Definitions » Accounts Receivable

Broncus Holding (HKSE:02216) Accounts Receivable : HK$71.22 Mil (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Broncus Holding Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Broncus Holding's accounts receivables for the quarter that ended in Jun. 2024 was HK$71.22 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Broncus Holding's Days Sales Outstanding for the quarter that ended in Jun. 2024 was 449.30.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Broncus Holding's Net-Net Working Capital per share for the quarter that ended in Jun. 2024 was HK$2.21.


Broncus Holding Accounts Receivable Historical Data

The historical data trend for Broncus Holding's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Broncus Holding Accounts Receivable Chart

Broncus Holding Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Accounts Receivable
24.89 22.76 40.15 66.94 77.78

Broncus Holding Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only 33.11 66.94 67.42 77.78 71.22

Broncus Holding Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


Broncus Holding Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Broncus Holding's Days Sales Outstanding for the quarter that ended in Jun. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=71.219/28.928*91
=449.30

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Broncus Holding's accounts receivable are only considered to be worth 75% of book value:

Broncus Holding's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2024 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(1153.334+0.75 * 71.219+0.5 * 33.809-59.333
-0--0.008)/527.198
=2.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Broncus Holding Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Broncus Holding's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Broncus Holding Business Description

Traded in Other Exchanges
N/A
Address
No. 88 Jiangling Road, Xixing Street, Room 801, 8th Floor, Building 8, Binjiang District, Hangzhou, CHN
Broncus Holding Corp is a medical device company focused on the development of interventional pulmonology products. It is engaged in the field of interventional pulmonology, providing lung solutions in China and globally. The integrated interventional pulmonology platform addresses the pain points of the existing diagnosis and treatment paradigms and unmet medical needs for lung diseases by improving the diagnosis and treatment effects of lung cancer and COPD. The company offers products like Archimedes System, LungPoint, BioStar, FleXNeedle Biopsy Needle, RF-II, and InterVapor System among others. Geographically, the company derives a majority of its revenue from the Chinese Mainland, and the rest from European Union, USA, and other regions.
Executives
Xu Hong 2101 Beneficial owner
Zi Zhenjun
Xin Nuo Tong Investment Limited 2201 Interest of corporation controlled by you
Qiming Corporate Gp Iv, Ltd. 2201 Interest of corporation controlled by you
Qiming Venture Partners Iv, L.p. 2101 Beneficial owner
Qiming Gp Iv, L.p. 2201 Interest of corporation controlled by you
Qm12 Limited 2101 Beneficial owner
Dinova Capital Limited
Dinova Venture Partners Gp Iii, L.p.
Broncus Biomedical Limited
Dinova Healthcare Gamma Fund (usd) L.p.
Computershare Hong Kong Trustees Limited 2301 Trustee
Dinova Healthcare (hong Kong) Co., Limited
Lake Bleu Capital (hong Kong) Limited 2102 Investment manager
Hang Zhou De Nuo Shang Wu Zi Xun Zi Xun You Xian Gong Si

Broncus Holding Headlines

No Headlines